Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor
Authors:
- 1 October 1998
- journal article
- research article
- Published by Springer Nature in Archives of Pharmacal Research
- Vol. 21 (5) , 581-590
Abstract
We developed a novel water-soluble camptothecin analogue, CKD602, and evaluated the inhibition of topoisomerase I and the antitumor activities against mammalian tumor cells and human tumor xenografts. CKD602 was a nanomolar inhibitor of the topoisomerase I enzyme in the cleavable complex assay. CKD602 was found to be 3 times and slightly more potent than topotecan and camptothecin as inhibitors of topoisomerase, respectively. In tumor cell cytotoxicity, CKD602 was more potent than topotecan in 14 out of 26 human cancer cell lines tested, while it was comparable to camptothecin. CKD602 was tested for thein vivo antitumor activity against the human tumor xenograft models. CKD602 was able to induce regression of established HT-29, WIDR and CX-1 colon tumors, LX-1 lung tumor, MX-1 breast tumor and SKOV-3 ovarian tumor as much as 80, 94, 76, 67, 87% and 88%, respectively, with comparable body weight changes to those of topotecan. Also the therapeutic margin (R/Emax: maximum tolerance dose/ED58) of CKD602 was significantly higher than that of topotecan by 4 times. Efficacy was determined at the maximal tolerated dose levels using schedule dependent i.p. administration in mice bearing L1210 leukemia. On a Q4d×4 (every 4 day for 4 doses) schedule, the maximum tolerated dose (MTD) was 25 mg/kg per administration, which caused great weight loss and lethality in <5% tumor bearing mouse. This schedule brought significant increase in life span (ILS), 212%, with 33% of long-term survivals. The ex vivo antitumor activity of CKD602 was compared with that of topotecan and the mean antitumor index (ATI) values recorded for CKD602 were significantly higher than that noted for topotecan. From these results, CKD602 warrants further clinical investigations as a potent inhibitor of topoisomerase I.Keywords
This publication has 12 references indexed in Scilit:
- Synthesis and antitumor activity of 7-substituted 20(RS)-camptothecin analoguesBioorganic & Medicinal Chemistry Letters, 1996
- Synthesis and in vitro cytotoxicity of (RS)-20-desethyl-20-substituted camptothecin analoguesBioorganic & Medicinal Chemistry Letters, 1996
- Enantioselective synthesis of 20(S)-camptothecin using sharpless catalytic asymmetric dihydroxylationTetrahedron: Asymmetry, 1995
- Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassayCancer Chemotherapy and Pharmacology, 1991
- Synthesis of water-soluble (aminoalkyl)camptothecin analogs: inhibition of topoisomerase I and antitumor activityJournal of Medicinal Chemistry, 1991
- DNA Topoisomerase I—Targeted Chemotherapy of Human Colon Cancer in XenograftsScience, 1989
- DNA topoisomerases as targets for chemotherapyThe FASEB Journal, 1988
- Topoisomerases: Novel therapeutic targets in cancer chemotherapyBiochemical Pharmacology, 1988
- Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.Journal of Biological Chemistry, 1985
- Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2Journal of the American Chemical Society, 1966